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Appropriate Sequence for Afatinib
and Cisplatin Combination Improves
Anticancer Activity in Head and Neck
Squamous Cell Carcinoma
Eleonore Longton, Kathleen Schmit, Maude Fransolet, François Clement and
Carine Michiels*
Unit of Biochemistry and cellular Biology, Namur Research Institut for LIfe Sciences, University of Namur, Namur, Belgium
Despite a better understanding in head and neck tumors pathogenesis as well as
improvements in radiotherapy and surgery, locally advanced head and neck squamous
cell carcinoma (HNSCC) remains of poor prognosis. One promising target is the
epidermal growth factor receptor (EGFR), which is overexpressed in the majority of
HNSCC and is associated to tumor progression and resistance to treatment. However,
in several clinical trials, the combination of EGFR inhibitors with chemotherapy and/or
radiotherapy generates moderate results. In this study, we investigated the anti-tumor
activity of afatinib, an irreversible pan-EGFR inhibitor, combined to cisplatin in different
schedules of exposure. For that, we used two human EGFR wild-type HNSCC
cell lines and we evaluated the cytotoxicity of the two drugs combined in different
sequences. The efficiency of each strategy was assessed by evaluating the effects
on cell cycle distribution, DNA damage, cell death and downstream pathways of
ErbB family receptors. We demonstrated that cisplatin treatment followed by afatinib
exposure displayed more cytotoxic effects than the opposite timing or than simultaneous
association. This higher anticancer activity is probably due to afatinib-induced cell cycle
arrest, which prevents the repair of cisplatin-induced DNA damage and promotes cell
death by various mechanisms including apoptosis. These data suggest the importance
of an appropriate timing administration between an EGFR inhibitor and a conventional
chemotherapy in order to obtain the best clinical benefit for patients with a head and
neck cancer.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy
worldwide and continues to remain of poor prognosis despite advancements in treatment options
(1). Currently, standard treatment of advanced HNSCC includes surgery, radiotherapy and
chemotherapy, with cisplatin being themost commonly used drug in HNSCC (2). However, despite
these intensive combined modality therapies, more than 50% of patients with advanced disease
develop loco-regional recurrence within 2 years, and 20–30 % of those patients develop distant
metastasis (3). These data underline the urgent need for development of more effective therapeutic
strategies, without increasing toxicity.
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Epidermal growth factor receptor (EGFR), a member of
HER (ErbB) family tyrosine kinase receptors that includes
EGFR (HER1/ErbB-1), HER2/neu (ErbB-2), HER3 (ErbB-3)
and HER4 (ErbB-4) (4, 5), is overexpressed in up to 90% of
patients with HNSCC (6). Ligand-induced homo- or hetero-
dimerization of HER family members (7) activates major
downstream signaling pathways, including Ras/Raf/MAPK
(8), PI3K/Akt (9) and/or PLC/PKC that are linked to cell
proliferation, DNA repair, survival, and differentiation (10–13).
Therefore, overexpression of EGFR enhances tumorigenesis and
is associated with treatment resistance and poor prognosis
(14, 15). In addition, it is postulated that EGFR signaling is
activated in response to DNA damage induced by radiation
therapy (16) and by chemotherapeutic agents including cisplatin
(17). Several EGFR targeted therapies have been developed and
approved for clinical use such as cetuximab, a monoclonal
antibody (18, 19), or tyrosine kinase inhibitors (TKIs), including
panitumumab, erlotinib, and gefitinib. Particularly in locally
advanced HNSCC, cetuximab combined to radiotherapy or
chemotherapy showed an improvement in overall survival
(20, 21). However, despite the clear advantages of combined
EGFR targeted therapy with radiation or chemotherapy, many
patients do not respond to anti-EGFR therapeutics (22–24)
or develop subsequently resistance (25). One of the potential
mechanisms of intrinsic or acquired resistance implicates the
upregulation/activation of other HER family receptors in the
presence of single receptor inhibition (26, 27). These findings
led to the development of inhibitors targeting the kinase domain
of all HER family members, the most promising one being
afatinib.
Afatinib, a second generation of pan-ErbB inhibitor,
irreversibly binds to EGFR, HER2 and HER4, and inhibits their
enzymatic activity. HER3 being a kinase-inactive, it needs hetero-
dimerization with other ErbB receptors and thus, it is indirectly
also blocked by afatinib (28–30). In preclinical studies, afatinib
demonstrated more prolonged suppression of receptor kinase
activity compared to reversible first-generation EGFR-TKIs
(28, 31) and it also showed activity in tumor cells resistant to
reversible EGFR inhibitors (32). Moreover, in several tumor cell
lines including non-small cell lung cancer (NSCLC), pancreatic
cancer and colorectal cancer, the irreversible inhibition of all
ErbB family receptors by afatinib resulted in an inhibition of
cellular growth and induced apoptosis (33). The U.S. Food and
Drug Administration (FDA) has approved afatinib for first-line
treatment of patients with locally advanced or metastatic NSCLC
with activating EGFR mutations (34, 35).
Preclinical studies and clinical trials in the treatment of head
and neck tumors have also demonstrated the interest of afatinib
used alone or combined with cytotoxic drugs or radiation therapy
(36–42). These studies suggest that afatinib may enhance the
antitumor activity of cytotoxic drugs. However, the sequence of
administration of afatinib and cisplatin, themost commonly used
chemotherapeutic agent in HNSCC has never been addressed
but could improve the therapeutic response while decreasing the
toxicity. Indeed, some preclinical studies have already shown the
importance of a sequential administration, particularly between
chemotherapies and EGFR inhibitors (43–46).
Therefore, in this study, we assessed the effects of different
sequences of afatinib combined to cisplatin on cell growth, cell
cycle distribution and induction of apoptosis in Cal27 and SQD9,
two EGFR wild-type HNSCC cell lines.
MATERIALS AND METHODS
Cell Culture
Cal27, a human tongue squamous cell carcinoma cell line,
was obtained from American Type Culture Collection (ATCC,
Rockville MD, USA). SQD9, a human laryngeal squamous cell
carcinoma cell line, was kindly provided by Prof. Pierre Sonveaux
(Université Catholique de Louvain, Brussels, Belgium). The cells
were kept in a humidified atmosphere containing 5% CO2 at
37◦C and the medium was changed 2–3 times per week. Cells
were cultured in Minimum Essential Medium (MEM) with
GlutaMAXTM (Thermo Fisher Scientific, Belgium) supplemented
with 10% heat-inactivated fetal bovine serum.
Incubation With Afatinib and Cisplatin
Cisplatin was purchased from Sigma-Aldrich (Belgium), stored
according to the manufacturer’s protocol and diluted in sterile
PBS. Afatinib was purchased from Selleckchem (distributed by
Absource Diagnostics GmbH, München, Germany), diluted in
DMSO and stored according to the manufacturer’s protocol.
Afatinib concentrations used in the study were derived from
serial dilutions in cell culture medium.
Cytotoxic Assay
Cytotoxicity was assessed by a colorimetric assay using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Cal27 and SQD9 were seeded in 24-well plates at a density of
40,000 cells per well and were incubated at 37◦C with 5% CO2
for 48 h with various concentrations of afatinib alone (range, 0–
100 nM/L) and cisplatin alone (range, 0–100 µM/L) to obtain
inhibitory concentration (IC) values. MTT solution was prepared
at a concentration of 2.5 mg/mL in phosphate-buffered saline
and 500 µL were added per well. After 2 h, media and MTT
solution were removed before adding lysis buffer. 1 h later, the
optic density was read with a microplate spectrophotometer at
570 nm. The MTT test measures the number of metabolically
active (viable) cells. Cell growth inhibition was expressed as
the percentage of absorbance of the different conditions at 48 h
compared with control culture at time 0. Regarding cytotoxicity
effect of the different sequences for 48 h, we decided to use the
cisplatin and afatinib concentrations at IC20 (i.e., concentration
causing 20% of growth inhibitor) in order to keep an adequate
number of cells in each well. The IC20 for afatinib was 10 nM/L
and 15 nM/L and the IC20 for cisplatin was 15 µM/L and 20
µM/L for Cal27 and SQD9 respectively.
Six differents conditions of incubation between afatinib and
cisplatin were tested (Figure 1A):
(1) Cells were incubated for 48 h in complete medium without
drug (CTL);
(2) Cells were incubated for 48 h in complete medium with
afatinib alone (A 48 h);
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(3) Cells were incubated for 48 h in complete medium with
cisplatin alone (C 48 h);
(4) Cells were incubated for 48 h in complete mediumwith the
two drugs simultaneously (A+ C 48 h);
(5) Cells were incubated for 48 h in complete medium with
afatinib for 24 h immediately by cisplatin for 24 h (A 24 h+ C
24 h);
(6) Cells were incubated for 48 h in complete medium with
cisplatin for 24 h immediately by afatinib for 24 h (C 24 h+ A
24 h).
In each experiment, triplicates were performed for each
condition (n = 3) and the assay was repeated in six independent
experiments to avoid any bias.
Protein Extraction and Western Blot
Analysis
Cells were seeded in 25 cm2 polystyrene flasks (Corning) at
a density of 520 000 cells per flask. 24 h later, the medium
was removed and replaced by the different solutions for 48 h.
Cells were harvested, lyzed, and western blot analyses were
performed as described previously by Sermeus and al. (4, 47).
Primary antibodies used were reported in Table 1. Finally, the
membranes were scanned with the Odyssey Infrared Imager
(Li-Cor Biosciences). The fluorescence was quantified using
the imagery software Odyssey V3.0 from the Odyssey Infrared
Imager (Li-Cor Biosciences).
Cell Cycle and Apoptosis Assays by Flow
Cytometry
Cells were seeded in 25 cm2 polystyrene flasks at a density of
520 000 cells per flask. For cell cycle analysis, two different
concentrations of afatinib were tested. After 24 h of incubation,
cells were collected by trypsinization, fixed with 70% cold ethanol
and stored at −20◦C. DNA staining was performed with a
solution containing RNase (5µg/ml) and 7-AAD (0.05 µg/µl).
Induction of apoptotic cell death by the different sequences of
incubation with afatinib and/or cisplatin was investigated using
Annexin V-FITC/Propidium Iodide assay (BD Biosciences).
Analysis was performed using a BD Bioscience FACSCalibur
flow cytometer while data were processed and analyzed
with ModFit 4.0 (Verity Software House). Three independent
experiments were performed.
Immunofluorescence Labeling and
Confocal Microscopy
Cells were seeded on glass coverslips in 24-well plates (Costar)
at a density of 40,000 cells per well. 24 h later, the medium was
removed and replaced for the different sequences of incubation
with afatinib and/or cisplatin. After 48 h of incubation, the
medium was removed and cells were fixed, permeabilized, and
labeled following the procedure described previously (48). The
primary antibody used was rabbit anti-phospho-histone H2AX
(9664, cell signaling, Leiden, Netherlands), diluted at 1:400 in
bovine serum albumin (BSA) 2% with phosphate buffer saline
(PBS) and incubated overnight at 4◦C in dark. The secondary
antibody used was Alexia 488 nm anti-rabbit diluted at 1:1000
(Fisher Scientific). Nuclei were stained with Hoechst (Thermo
Fisher Scientific H-21491) at 2µg/mL at room temperature in
the dark for 1 h. The coverslips were finally mounted on slides
in Mowiol mounting solution (Sigma) warmed at 57◦C. Slides
were kept at 4◦C to be observed later under a confocal laser
scanning fluorescence microscope (SP5, Leica) with a constant
photomultiplier.
Statistics
Statistical analysis of the data was performed using Prism 6.04
(GraphPad Software, Inc., La Jolla, CA, USA). Due to the lack
of a normal distribution and the number of measurements, data
regarding cytotoxicity were evaluated using a nonparametric
Mann-Whitney U test. All of the experiments were repeated
at least three times. P ≤ 0.05 was considered to indicate a
statistically significant difference.
RESULTS
Sequence-Dependent Antiproliferative
Effects of Afatinib and Cisplatin in Cal27
and SQD9 Cell Lines
To determine whether an increase in the antiproliferative activity
could be obtained by an appropriate schedule of cisplatin and
afatinib combination, different treatment sequences were tested
in Cal27 and SQD9 cells (Figure 1A). Cisplatin and afatinib
inhibitory concentration (IC) values were determined by MTT
assay in the two cell lines (Supplementary Data 1). In order to
study the cytotoxic effect of the different combinations between
afatinib and/or cisplatin with an adequate number of viable cells,
we decided to use the cisplatin and afatinib concentrations at
IC20 (i.e., concentration causing 20% of growth inhibition). The
IC20 for afatinib was 10 nM/L and 15 nM/L and the IC20 for
cisplatin was 15 µM/L and 20 µM/L for Cal27 and SQD9 cells
respectively. In both cell lines, we observed that exposure to
afatinib alone (A 48 h) and afatinib followed by cisplatin (A
24 h + C 24 h) induced a cytostatic effect after 48 h. A cytotoxic
effect was observed with exposure to cisplatin for 48 h (C 48 h),
without any significant difference when afatinib was added to
cisplatin simultaneously (C + A 48 h) compared to cisplatin
alone. However, when cisplatin was incubated 24 h before afatinib
(C 24 h + A 24 h), we observed the most important cytotoxicity,
which was statistically significant compared to cisplatin alone
(Figure 1B).
In order to know if the cytotoxicity detected by the MTT
assay is due to apoptosis, the abundance of cleaved PARP and
cleaved caspase 3 has been investigated by western blot in Cal27
and SQD9 cells. The exposure to cisplatin alone for 48 h (C
48 h) induced a high level of cleaved PARP and cleaved caspase
3. Cleaved PARP and cleaved caspase 3 levels were lower when
cisplatin and afatinib were added simultaneously (C + A 48 h)
or when afatinib was added before cisplatin (A 24 h + C 24 h;
Figure 1C, quantification in Supplementary Data 2). However,
when afatinib was added 24 h after cisplatin (C 24 h + A 24 h),
we observed a more important cleavage of PARP and a similar
cleaved caspase 3 level than cisplatin alone in both cell lines.
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FIGURE 1 | Effects of afatinib and cisplatin on the growth and apoptotic cell death. (A) Schematic representation of the six different conditions tested with afatinib
and/or cisplatin on Cal27 and SQD9 cells. Cells were incubated for 48 h without drug (CTL), or with afatinib alone (A 48 h), with cisplatin alone (C 48h), or with the two
drugs simultaneously (A + C 48h). Cells were also incubated with drugs added sequentially: afatinib was added for 24 h before being replaced by cisplatin for 24 h (A
24 h + C 24h), or cisplatin was added for 24 h and followed by afatinib for 24 h (C 24 h + A 24h). (B) Cal27 and SQD9 cells were treated with the different
combinations of afatinib and/or cisplatin for 48 h and viable cell number was analyzed by MTT assay. Data are represented as median ± interquartile range (n = 6) with
reference to untreated control at time 0 (harvested after 24 h of culture). Mann Whitney statistical analysis were performed, ns: p > 0.05, *p < 0.05. (C) After 48 h of
incubation with the different sequences of afatinib and/or cisplatin, Cal27, and SQD9 cell total proteins were collected. The abundance of total and cleaved forms of
PARP and caspase 3 were assessed by western blot analysis with β-actin used as a loading control. (D) Cal27 and SQD9 cells were incubated with the different
sequences of afatinib and/or cisplatin for 48 h. After the incubation, cells were harvested with trypsin/EDTA and stained using Annexin V-FITC (AnnV) and propidium
iodine (PI) to detect apoptosis. The results were analyzed by flow cytometry. Cells were divided in 4 groups: Ann–/PI- for viable cells, AnnV+/PI– for cells in early
apoptosis phase, AnnV+/PI+ for cells in late apoptosis, AnnV–/PI+ for cells in necrosis phase. Data are represented as mean ± SD of triplicate.
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TABLE 1 | Antibodies used for western blot analyses.
Protein Primary antibody Secondary antibody
EGFR Anti-EGFR
(Rabbit, Cell Signaling Technology, #4267, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
Phospho-EGFR
(Tyr1173)
Anti-phospho-EGFR
(Rabbit, Invitrogen, #44794G, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
ERK 1/2 p44/42 Anti-ERK
(Rabbit, Cell Signaling Technology, #9102, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
Phospho-ERK 1/2 p44/42
(Thr202/Tyr204)
Anti-phospho-ERK
(Mouse, Cell Signaling Technology, #9106, 1/1000)
IRDye 680RD
(Anti-mouse, Li-Cor Biosciences 926-68070, 1/10000)
AKT Anti-AKT
(Rabbit, Cell Signaling Technology, #9272, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
Phospho-AKT
(Ser473)
Anti-phospho-AKT
(Rabbit, Cell Signaling Technology, #9271, 1/1000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
Caspase 3 Anti-Caspase 3
(Rabbit, Cell Signaling Technology, #9662, 1/2000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
Cleaved Caspase 3 Anti-Cleaved Caspase 3
(Rabbit, Cell Signaling Technology, #9664, 1/2000)
IRDye 800CW
(Anti-rabbit, Li-Cor Biosciences 926-32211, 1/10000)
PARP Anti-PARP
(Mouse, BD Biosciences 51-6639GR, 1/1000)
IRDye 680RD
(Anti-mouse, Li-Cor Biosciences 926-68070, 1/10000)
These results were confirmed using the Annexin V-FITC flow
cytometric assay. Cells were divided in 4 groups: Ann-/PI-
for viable cells, AnnV+/PI- for cells in early apoptosis phase,
AnnV+/PI+ for cells in late apoptosis, AnnV-/PI+ for cells in
necrosis phase (Supplementary Data 3). We have not observed
any significant increase in apoptotic cell death when cells were
incubated with afatinib alone for 48 h or with afatinib added
24 h before cisplatin, compared to untreated cells. In contrast,
cisplatin exposure for 48 h induced an important increase in late
apoptosis. This induction of apoptotic cell death by cisplatin was
higher when afatinib exposure followed the cisplatin incubation
(Figure 1D and Supplementary Data 3).
Biological Mechanisms Underlying the
Sequence-Dependent Effect of Afatinib
and Cisplatin
In order to explain the molecular mechanisms underlying
the sequence-dependent antiproliferative effects of afatinib and
cisplatin in Cal27 and SQD9 cells, we investigated the effect
of each drug on EGFR signaling pathways. First, afatinib being
an irreversible ErbB family blocker, its effects on the mRNA
expression of EGFR as well as the mRNA expression of other
ErbB family receptors (HER2, HER3 and HER4) were evaluated
in Cal27 and SQD9 cells after 24 h of incubation. We also
investigated the effect of cisplatin on these ErbB receptors for
each human HNSCC line after 24 h of exposure. The results
showed that afatinib decreased the mRNA expression of EGFR,
HER2 and HER3, in Cal27 and slightly affected the mRNA
expression of these ErbB receptors in SQD9 cells (Figure 2A).
Interestingly, cisplatin induced a more important decrease in the
EGFR, HER2, and HER3 expression of both cell lines. HER4 is
not expressed in any of these two cell lines.
Then, the effects of afatinib and/or cisplatin in different
sequences on the two major EGFR downstream signaling
pathways, Ras/Raf/MAPK and PI3K/Akt were analyzed. Low
nanomolar concentration of afatinib inhibited the activation of
EGFR, AKT, and ERK1/2 in both cell lines. As already observed
with mRNA expression level, the results showed a decrease
in total EGFR protein level in cisplatin-treated cells. However,
an increase in EGFR phosphorylation was detected. Similarly,
an activation of Akt and ERK1/2 was induced by cisplatin
(Figure 2B, quantification in Supplementary Data 4).
We also assessed the effect of afatinib on cell cycle. Flow
cytometry analyses were performed on SQD9 and Cal27 cells 24 h
after incubation with two different concentrations of afatinib.
The results showed that afatinib affected the cell cycle of Cal27
and SQD9 cells: a concentration-dependent increase in the
fraction of cells in the G0/G1 phase of the cell cycle from 65 to
82% at 10 nM of afatinib and to 84% at 15 nM of afatinib for
Cal27, and from 77% to 82% at 15 nM of afatinib and to 86% at
20 nM of afatinib for SQD9 was observed, with a concomitant
reduction of the fraction of cells in the S and G2/M phases
(Figure 2C).
To study the combined effect of afatinib with cisplatin
on DNA damage, phosphorylated γH2AX foci, a marker
for DNA double-strand breaks, were analyzed. In both
cell lines, after 48 h of incubation with afatinib (A 48h),
no increase in γH2AX foci was observed compared to
the untreated cells (CTL). This suggests that the cytostatic
effect observed with afatinib is not related to DNA damage.
Conversely, we observe a clear cytotoxicity effect induced
by cisplatin incubation (C 48 h) with an important increase
in the number of γH2AX foci per cell compared to
untreated cells (CTL). This number of cisplatin-induced
γH2AX foci decreased when afatinib was added before or
simultaneously to cisplatin. However, the sequence with cisplatin
followed by afitinib (C 24 h + A 24 h) appeared to be the
most effective in terms of cytotoxicity and DNA damage
(Figure 3).
Frontiers in Oncology | www.frontiersin.org 5 October 2018 | Volume 8 | Article 432
Longton et al. Afatinib and Cisplatin Sequence for HNSCC
FIGURE 2 | Effects of afatinib and cisplatin incubation on ErbB family receptor mRNA expression, EGFR signaling pathways and cell cycle distribution in Cal27 and
SQD9 cells. (A) Cells were incubated with cisplatin or afatinib at IC20 for 24 h. Total RNA was extracted and reverse transcription was performed before mRNA
expression level analysis by RT-qPCR. 23 kDa was used as housekeeping gene. Graphs showed the values of fold induction compared to cells incubated with no
drug (CTL). Values are presented as mean ± SD (n = 3; B) Cells were incubated with the different sequences of cisplatin and/or afatinib for 48 h. Cell lysates were
analyzed by western blot analysis. β-actin was used as a loading control. (C) Cal27 cells were incubated with afatinib at 10 nM and 15 nM and SQD9 cells were
exposed to afatinib at 15 nM and 20 nM for 24 h. Then, cells were fixed and stained with 7-AAD and DNA content was measured by flow cytometry analysis. Cells
were divided in 3 groups: G0/G1 phase (2n), S phase (2n−4n) and G2/M phase (4n). One representative experiment is shown for each cell line. Graphs show the
percentage of cells in each cell cycle phase. Values are presented as mean ± SD (n = 3).
DISCUSSION
EGFR overexpression is observed in many types of cancer,
including head and neck, where it plays an important role in
tumor proliferation, survival, vascularization, and metastasis.
Moreover, EGFR is often activated in response to DNA
damage caused by chemotherapy and/or radiation therapy (16,
17). This activation induces a survival response responsible
for the resistance to treatment. In this situation, combining
EGFR targeted drugs with cytotoxic drugs and/or radiation
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FIGURE 3 | Effects of afatinib and cisplatin incubation on DNA damages. Cal27 and SQD9 cells were plated on glass cover slips and incubated and incubated with
the different sequences of cisplatin and/or afatinib for 48 h. Then, cells were washed, labeled and observed under a confocal H2AX foci.
therapy that have different mechanisms of action could improve
the therapeutic effectiveness. However, several clinical studies
showed that combined anti-EGFR therapies with conventional
chemotherapy and/or radiation generated conflicting results (29,
49). This can be explained by the resistance to EGFR targeted
inhibitors, probably due to further upregulation/activation of the
other members of the ErbB family, like HER2 and HER3 tyrosine
kinases. These observations led to the development of inhibitors
targeting all HER family members, the most promising one being
afatinib. Afatinib is an irreversible EGFR/HER2/HER4 tyrosine
kinase inhibitor. Afatinib used alone or combined with cytotoxic
drugs or radiation therapy could be efficient in the treatment
of head and neck tumors. A previous in vitro study using one
single human hypopharyngeal cell line (FaDu) demonstrated
that afatinib had a dose-dependent antiproliferative effect (40).
Another in vitro study performed on five human EGFR wild-
type HNSCC cell lines showed that afatinib in combination
with cisplatin increased the growth inhibiting effect of this
drug (36). Similar, an in vivo study highlighted that afatinib
combined with gemcitabine had more significant antitumor
effect than each drug used alone in a nasopharyngeal xenograft
model (42). More recently, a study using both in vitro
and in vivo models showed the interest of afatinib as a
radiosensitizer in HNSCC cells by targeting cancer stem cells
(38). Recently, it was also shown that afatinib maintained
its cytotoxicity in cetuximab-resistant HNSCC cell lines (50).
Afatinib also demonstrated a higher activity during clinical
trials in comparison with other EGFR inhibitors. In a phase
II study comparing the efficacy of cetuximab with afatinib in
patients with platinum-refractory metastatic/recurrent HNSCC,
the authors observed comparable response rates and suggested
a possible effectiveness of afatinib in patients pre-treated
with therapy targeting EGFR (41). In the phase III LUX-
Head & Neck1 (LHN1) trial, afatinib significantly improved
progression-free survival (PFS) vs. methotrexate treatment alone
in recurrent and/or metastatic HNSCC patients progressing
on/after platinum-based therapy, regardless of age (37, 39).
Another hypothesis proposed to explain the resistance to EGFR
inhibitors combined to cytotoxic drugs could be related to a
schedule-dependent cytotoxic effect. Indeed, some studies, which
combined chemotherapies and EGFR inhibitors, evidenced the
importance of timing administration between the molecules.
For example, it was already demonstrated that gemcitabine
treatment followed by gefitinib was more cytotoxic than the
opposite timing (43) or concomitant administration. The same
results have been observed for combination of oxaliplatin and
EGFR targeted treatments such as gefitinib and cetuximab
(44–46).
Therefore, in this in vitro study, we investigated the
effectiveness of afatinib, an irreversible EGFR/HER2/HER4
tyrosine kinase inhibitor, in combination with cisplatin, the
most common chemotherapy used in HNSCC, in various
sequences of treatment in two human EGFR wild-type HNSCC
cell lines. The results showed different cytotoxic effects of
cisplatin-associated-afatinib depending on the drug schedule.
We observed a significant antiproliferative effect of afatinib
combined to cisplatin only when SQD9 and Cal27 cells
were incubated with cisplatin for 24 h followed by afatinib
for 24 h. In contrast to the results of a previous in vitro
study (36), we did not observe any influence of afatinib
on the cytotoxic effect of cisplatin when these drugs were
combined simultaneously. Contrariwise, initial exposure to
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afatinib seemed to protect cells from subsequent treatment with
cisplatin.
The importance of using an appropriate sequence to combine
afatinib with cisplatin can be explained by their respective
effects on growth factor signaling pathways and cell cycle
progression. Indeed, it is postulated that the response to cisplatin-
induced DNA damages implicates Src kinase activation, which
is responsible for the EGFR autophosphorylation (17). The
EGFR activation induces a survival response that reduces the
efficacy of cisplatin. EGFR activation after 24 and 48 h of
cisplatin incubation was indeed observed, and we also observed
a clear activation of Akt and ERK1/2 in CAL27 and SQD9
cells exposed to cisplatin. Afatinib, by inhibiting the tyrosine
kinase activity of EGFR, leads to the inhibition of the PI3K/Akt
and RAS/Raf/ERK1/2 pro-survival pathways in both cell lines
(51). By these means, afatinib also establishes a G0/G1 cell
cycle arrest, as demonstrated in previous studies in HNSCC
(38, 52). We also observed a dose-dependent cell-cycle arrest
in the G0/G1 phase after 24 h of afatinib exposure. Hence, this
arrest of cells in G1 phase prevents the action of cisplatin,
since this drug requires cells entering in S phase to exert its
cytotoxic activity. This explains in part why afatinib antagonizes
the cytotoxic activity of cisplatin when it is added simultaneously
or before cisplatin incubation. Conversely, when afatinib is added
24 h after cisplatin, it decreases the fraction of cells in the S-
phase, hence preventing the repair of DNA damage caused by
cisplatin, which promotes cell death by different mechanisms
including apoptosis. Indeed, our results showed a higher number
of γH2AX foci in cisplatin-treated cells compared to control
or afatinib-treated cells. The number of γH2AX foci was even
higher when afatinib was added 24 h after cisplatin, suggesting
that afatinib induced a blockade of the DNA repair. In parallel,
more apoptotic cell death was demonstrated when the cells were
incubated with cisplatin and then afatinib compared to cisplatin
alone.
The objective of our study was to try to understand why the
clinical trials mentioned hereabove did not improve the outcome
of the patients. EGFR inhibition provokes cell cycle arrest that
prevents DNA damage repair induced either by X-ray irradiation
or cisplatin. It also decreases the cell repopulation between 2
fractions of radiotherapy. On the opposite, cell cycle arrest before
or during the treatment may protect cells from the efficacy of
these two treatments. Our results are in accordance with the
clinical observations of Ang et al. (22) and the CONCERT studies
and although they do not prove that EGFR-inhibition after
chemo-radiotherapy would have worked better, they provide
a possible explanation for the failure of these trials to meet
their objective. Our results demonstrate that the sequence of
the administration of the two drugs/therapies must be carefully
studied in order to improve the therapeutic effectiveness.
Nowadays, several clinical studies combine different therapies,
including chemotherapy and radiation therapy, but also targeted
therapies and immunotherapy. While they seem very promising,
they have their own specific biomolecular effects. In our
opinion, preclinical studies will remain an important step in
the evaluation of optimal timing, duration, and dose between
multiple therapies combined together. Our data support the
hypothesis that afatinib is a good partner associated with cisplatin
but, based on an understanding of the molecular mechanisms
of each drug, demonstrate the importance of optimizing the
right timing. Indeed, our results show that cisplatin followed
by afatinib could be the optimal sequence in HNSCC treatment
in order to obtain more tumor control. In addition, we also
demonstrate that initial exposure to afatinib could protect cells
from subsequent treatment with cisplatin and thus should be
avoided. Although this in vitro study is based on two HNSCC
cell lines and needs to be validated in vivo, it highlights the
interest of translational researches, particularly important for
oncologists and radiation oncologists when different therapies
are combined.
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